<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley Cohen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Virginia Reddy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E William St Clair, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1975719368"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The Janus kinases (JAKs) are protein tyrosine kinases (TYKs) that bind to transmembrane type 1 and type 2 cytokine receptors and mediate cellular responses to numerous cytokines and growth factors; these mediators are important in immune defense and in immune-mediated disease. Several pharmacologic JAK inhibitors (JAKi or Jakinibs) are commercially available for clinical use as oral and topical agents for immune-mediated and inflammatory diseases, although the availability of various JAK inhibitors varies among countries and regions.</p><p>JAK inhibitors are highly targeted molecules with relatively simple chemical structures in comparison to therapeutic agents made by recombinant deoxyribonucleic acid (DNA) techniques (and thus termed "biologics"), such as monoclonal antibodies and soluble truncated membrane receptors. Unlike biologics, the JAK inhibitors can be orally administered, although some are available for topical use.</p><p>Major established and investigational uses of JAK inhibitors include the treatment of several forms of inflammatory arthritis in adults and children (eg, rheumatoid arthritis [RA], psoriatic arthritis, juvenile idiopathic arthritis, spondyloarthritis, systemic lupus erythematosus) and other inflammatory disorders (eg, inflammatory bowel disease, atopic dermatitis, psoriasis, alopecia areata, vitiligo). They are also used in the management of hematologic disorders (eg, myelofibrosis, polycythemia vera, graft-versus-host disease) and in other conditions.</p><p>The biology and general considerations regarding the use of these agents for rheumatologic and other inflammatory disorders are presented here. The use of these agents for the treatment of specific inflammatory and autoimmune conditions, including the following and other conditions, is described in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>RA (see  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'JAK inhibitor therapy'</a> and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'JAK inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriatic arthritis (see  <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Axial disease resistant to initial tumor necrosis factor inhibitor'</a> and  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis", section on 'Janus kinase inhibitor for patients with concomitant axial disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Axial spondylarthritis (see  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Janus kinase inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyarticular juvenile idiopathic arthritis (see  <a class="medical medical_review" href="/z/d/html/6428.html" rel="external">"Polyarticular juvenile idiopathic arthritis: Treatment", section on 'Tofacitinib'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriatic juvenile idiopathic arthritis (see  <a class="medical medical_review" href="/z/d/html/16366.html" rel="external">"Psoriatic juvenile idiopathic arthritis: Management and prognosis", section on 'Spondylitis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriasis (see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Emerging therapies'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerative colitis (see  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Small molecules'</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Maintenance therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atopic dermatitis (eczema) (see  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'JAK inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia areata (see  <a class="medical medical_review" href="/z/d/html/3319.html" rel="external">"Alopecia areata: Management", section on 'Oral baricitinib'</a> and  <a class="medical medical_review" href="/z/d/html/3319.html" rel="external">"Alopecia areata: Management", section on 'Oral ritlecitinib'</a> and  <a class="medical medical_review" href="/z/d/html/3319.html" rel="external">"Alopecia areata: Management", section on 'Other Janus kinase inhibitors'</a>)</p><p></p><p class="headingAnchor" id="H3250292462"><span class="h1">JANUS KINASE BIOLOGY AND FUNCTION</span></p><p class="headingAnchor" id="H40331208"><span class="h2">Role of Janus kinases in receptor-mediated signaling</span><span class="headingEndMark"> — </span>Janus kinases (JAKs) are members of a family of protein tyrosine kinases (TYKs) that facilitate cell signaling. Many of the major receptors that trigger the activation of immune cells are activated via protein phosphorylation, which is mediated by protein TYKs [<a href="#rid1">1,2</a>]. The JAKs are intracytoplasmic protein TYKs that bind to the cytoplasmic region of transmembrane cytokine receptors and promote signal transduction.</p><p>In particular, JAKs mediate signaling through type 1 and type 2 cytokine receptors [<a href="#rid3">3</a>]. Once the cytokine receptor interacts with a ligand, such as a cytokine or growth factor, JAKs associated with the receptor are activated, leading to tyrosine phosphorylation of the receptor, which then leads to activation of signal transducer and activators of transcription (STATs)  (<a class="graphic graphic_figure graphicRef132371" href="/z/d/graphic/132371.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. The STATs translocate to the nucleus and modulate transcription of effector genes. Cellular responses to JAK/STAT signaling may thus include proliferation, differentiation, migration, apoptosis, and cell survival.</p><p class="headingAnchor" id="H2380815723"><span class="h2">Janus kinase isoforms</span><span class="headingEndMark"> — </span>There are four isoforms of JAKs: JAK1, JAK2, JAK3, and TYK2, which mediate signaling in pairs specifically associated with particular cytokine and growth-factor receptors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>JAK1</strong> – JAK1 is important for signaling of receptors activated by interleukin (IL) 6, IL-10, IL-11, IL-19, IL-20, IL-22, and interferon (IFN) alpha, IFN-beta, and IFN-gamma. JAK1 can be paired with any of the three other members of the JAK family, depending upon the associated receptor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JAK2</strong> – JAK2 is important for signaling for hormone-like cytokines erythropoietin, thrombopoietin, growth hormone, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, and IL-5. JAK2 can pair with JAK1, TYK2, or another JAK2 molecule, depending upon the associated receptor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JAK3</strong> – JAK3 is expressed in hematopoietic cells and is activated when the relevant cytokine receptor for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 binds to its respective ligand. These cytokines are important for lymphocyte activation, function, and proliferation. JAK3 only signals in combination with JAK1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TYK2</strong> – TYK2 pairs with either JAK1 or JAK2 or another TYK2 molecule to facilitate signaling for IL-12, IL-23, and type 1 IFNs.</p><p></p><p>The JAKs are <strong>not</strong> involved with signaling pathways for IL-1 or tumor necrosis factor (TNF).</p><p class="headingAnchor" id="H3790528763"><span class="h1">MECHANISM OF ACTION OF JANUS KINASE INHIBITORS</span></p><p class="headingAnchor" id="H1428225822"><span class="h2">Broad cytokine and growth factor inhibitory effects</span><span class="headingEndMark"> — </span>Janus kinase (JAK) inhibitors are small, orally active drugs that are categorized as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). They suppress multiple cytokine and growth factor receptor signaling pathways, in contrast to biologic DMARDs (bDMARDs), which are designed to target a specific cytokine, cytokine receptor, or another cell surface molecule. The clinical efficacy and safety profiles of the JAK inhibitors when used for the treatment of rheumatoid arthritis (RA) are generally comparable with the bDMARDs, such as the tumor necrosis factor (TNF) inhibitors and interleukin (IL) 6 inhibitors.</p><p>The JAK inhibitors reversibly and irreversibly bind to JAK proteins inside cells, which prevents the JAKs from transphosphorylating the associated cytokine and growth factor receptor. As a result, the cytokine or growth factor receptor fails to activate the dedicated pair of signal transducer and activators of transcription (STATs) family members (STAT1-STAT6) [<a href="#rid5">5</a>]. The JAK inhibitors are thus also sometimes referred to as JAK/STAT inhibitors.</p><p>Their broad inhibitory properties have led to the use of JAK inhibitors in inflammatory arthritis of various types in both adults and children and in autoinflammatory diseases. JAK/STAT inhibition with these agents is also employed in disorders mediated by interferon (IFN) production (interferonopathies), including some disorders with recurrent infection and autoimmunity that result from gain-of-function variants in the <em>STAT1</em> gene. T cell-mediated diseases, such as alopecia areata, vitiligo, and atopic dermatitis, have been explored or established as other potential indications for these agents. (See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"</a> and  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Signal transducer and activator of transcription (STAT1) dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'Autosomal dominant GOF STAT1 deficiency'</a>.)</p><p class="headingAnchor" id="H3301717498"><span class="h2">Effects mediated by inhibition of IL-6 signaling</span><span class="headingEndMark"> — </span>JAK1 inhibition interferes with signaling through the interleukin (IL) 6 receptor, which probably accounts in part for its clinical efficacy in many clinical settings, as well as some of its side effects, such as neutropenia and hyperlipidemia, which are also associated with the use of IL-6 receptor monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">sarilumab</a>). (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H1063907715"><span class="h2">Selectivity of Janus kinase inhibitors for specific Janus kinases</span><span class="headingEndMark"> — </span>JAK inhibitors available for clinical use differ in their selectivity for specific JAK isoforms. However, it is not clear how this apparent JAK selectivity in the laboratory and in experimental animal models extrapolates to meaningful differences among these agents in their clinical efficacy across the spectrum of chronic inflammatory diseases. At concentrations equivalent to clinically effective doses, the JAK inhibitors overall appear to be less selective for particular JAK isoforms than when evaluated in cellular and biochemical assays [<a href="#rid5">5,6</a>]. <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and peficitinib are considered pan-JAK inhibitors by regulatory authorities, while <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> is considered a highly selective JAK1 inhibitor but also inhibits JAK2 and tyrosine kinase (TYK) 2. Filgotinib is a highly selective JAK1 inhibitor in biochemical and other cellular and whole blood laboratory testing [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H146022749"><span class="h2">Distinguishing characteristics of individual agents</span></p><p class="headingAnchor" id="H2667659083"><span class="h3">Tofacitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> reversibly inhibits JAK1 and JAK3 in vitro and to a lesser extent inhibits JAK2 and TYK2 [<a href="#rid6">6,8</a>]. Tofacitinib, by inhibition of JAK3, inhibits cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21; and by JAK1 inhibition, inhibits IL-6, type 1 IFNs, and IFN-gamma.</p><p><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> is available as immediate-release and extended-release tablets, as well as an oral solution. Extended-release tablets are widely used because of their convenience, but there has been very little formal comparison of the immediate- and extended-release formulations in clinical trials [<a href="#rid9">9</a>]. Tofacitinib is approved for RA, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. (See  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib'</a>.)</p><p class="headingAnchor" id="H1336261884"><span class="h3">Baricitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">Baricitinib</a> reversibly inhibits JAK1 and JAK2, moderately inhibits TYK2, and only modestly inhibits JAK3 in in vitro and in animal models of arthritis in rats and mice [<a href="#rid6">6,10</a>]. It is administered orally in tablet form. With JAK1 inhibition, IL-6 and type 1 IFNs and IFN-gamma are inhibited. With JAK2 inhibition, growth factors erythropoietin, thrombopoietin, and granulocyte-macrophage colony-stimulating factor (GM-CSF) are inhibited. It is approved for use after conventional synthetic DMARD (csDMARD) failure in patients with RA outside of the United States and for use after TNF inhibitor failure in patients with RA in the United States. (See  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Baricitinib'</a>.)</p><p>In addition to immunomodulatory effects, the use of <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> in patients with coronavirus disease 2019 (COVID-19) is thought to have potential antiviral effects through interference of viral entry and has been approved for patients 18 years and older who are hospitalized and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Baricitinib and JAK inhibitors'</a>.)</p><p>JAK1/2 inhibitors such as <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> have been under investigation for treatment of autoinflammatory diseases mediated by IFN production and signaling (interferonopathies) because type 1 IFNs signal in part via JAK1. It is commercially available in Europe for atopic dermatitis, where IL-4, IL-5, and IL-13, cytokines preferentially inhibited by baricitinib, may play a role. Baricitinib has also been used to treat the autoimmune manifestations in chronic mucocutaneous candidiasis that is attributable to gain-of-function defects in signal transducer and activator of transcription 1 (<em>STAT1</em>). (See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H399632040"><span class="h3">Upadacitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">Upadacitinib</a> demonstrates in vitro selectivity for JAK1 [<a href="#rid11">11</a>]. Thus, it effectively inhibits IL-6- and IFN-gamma-related signaling, with less effect on natural killer cell depletion compared with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>.</p><p><a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">Upadacitinib</a> is administered as a 15 mg oral tablet in a 24-hour extended-release formulation.</p><p>Similar to <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, a reportedly selective JAK1 inhibitor, is under investigation for treatment of autoinflammatory diseases mediated by IFN production and signaling (interferonopathies) based upon the rationale that type 1 IFNs signal in part via JAK1. It is approved for treatment of RA, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, atopic dermatitis, Crohn disease, and ulcerative colitis. (See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'Therapeutic trial'</a>.)</p><p class="headingAnchor" id="H4017940390"><span class="h3">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Filgotinib</strong> – Filgotinib is considered a highly selective JAK1 inhibitor. Filgotinib is approved for use in Europe and in Japan for the treatment of RA [<a href="#rid12">12,13</a>]. Its manufacturer did not seek approval in the United States for rheumatic diseases [<a href="#rid14">14</a>]. Filgotinib may be associated with a lower risk of herpes zoster when compared with other JAK inhibitors, although this feature has not been well established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peficitinib</strong> – Peficitinib is an orally bioavailable, once-daily JAK inhibitor for the treatment of patients with RA with an inadequate response to DMARDs, including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Peficitinib is a pan-JAK inhibitor that binds irreversibly to JAK1, JAK2, JAK3, and TYK2 [<a href="#rid15">15,16</a>]. Peficitinib, which binds irreversibly to the JAKs, appears to function as a pan-JAK inhibitor. Peficitinib is approved for use in Japan and Korea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ruxolitinib</strong> – <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">Ruxolitinib</a> is a JAK1/2 inhibitor orally administered as a tablet. A topical form is available for the treatment of atopic dermatitis and vitiligo. It has been used primarily for the treatment of acute and chronic graft-versus-host disease, myelofibrosis, and polycythemia vera. In addition, oral JAK1 inhibitors such as ruxolitinib are under investigation for treatment of several different autoinflammatory diseases mediated by IFN production and signaling (interferonopathies) owing to their ability to interfere with type 1 IFN signaling pathways. Additionally, ruxolitinib has been used to treat chronic mucocutaneous candidiasis with associated autoimmunity due to gain-of-function defects in <em>STAT1</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abrocitinib</strong> – <a class="drug drug_general" data-topicid="134831" href="/z/d/drug information/134831.html" rel="external">Abrocitinib</a> is a JAK1 inhibitor available for the treatment of atopic dermatitis in adults and adolescents. It is typically administered orally once daily. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'JAK inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141857" href="/z/d/drug information/141857.html" rel="external">Ritlecitinib</a> – Ritlecitinib is a JAK inhibitor that is available for the treatment of severe alopecia areata in adults and adolescents. It selectively inhibits JAK3 and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) kinase family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational agents</strong> – A number of JAK inhibitors in oral and topical formulations are under investigation but not available for routine clinical use. These include <a class="drug drug_general" data-topicid="139596" href="/z/d/drug information/139596.html" rel="external">deucravacitinib</a>, a selective TYK2 inhibitor that is under investigation for the treatment of psoriatic arthritis and systemic lupus erythematosus, and is approved for the treatment of psoriasis [<a href="#rid17">17-19</a>]; a TYK2/JAK1 inhibitor for psoriasis [<a href="#rid18">18</a>]; and a JAK1/TYK2 inhibitor for refractory dermatomyositis [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Various JAK inhibitors are also in development for the treatment of juvenile idiopathic arthritis (<a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>), systemic juvenile idiopathic arthritis (<a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>), and systemic lupus erythematosus (upadacitinib).</p><p></p><p class="headingAnchor" id="H175391983"><span class="h1">PRETREATMENT SCREENING AND PRECAUTIONS</span></p><p class="headingAnchor" id="H646019955"><span class="h2">Clinical and laboratory screening and evaluation</span><span class="headingEndMark"> — </span>Similar testing protocols are appropriate for all of the available Janus kinase (JAK) inhibitors. We perform the following screening and evaluation before initiating treatment with a JAK inhibitor:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical history</strong> – Patients should be screened for a history of conditions that may increase the risk for certain complications of JAK inhibitor therapy, including a history of diverticulitis, gastrointestinal tract perforation, thrombosis, current or past smoking and other cardiovascular risk factors, and malignancy (other than a successfully treated nonmelanoma skin cancer). A history of tumor necrosis factor (TNF) inhibitor use and the response to therapy should also be ascertained. (See <a class="local">'Restrictions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Patients are at risk for cytopenias, dyslipidemias, and liver injury, as well as reactivation of latent tuberculosis [<a href="#rid21">21</a>] and reactivation or exacerbation of hepatitis B [<a href="#rid22">22,23</a>] and possibly hepatitis C [<a href="#rid24">24</a>] (see <a class="local">'Adverse effects'</a> below). Thus, baseline laboratory studies should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with differential white count and platelet count.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), bilirubin, and alkaline phosphatase.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lipid panel, including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for latent tuberculosis, hepatitis B (including testing for hepatitis B virus [HBV] surface antigen and HBV core antibody), and hepatitis C virus (HCV). (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a> and  <a class="medical medical_review" href="/z/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children"</a> and  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy testing and reproductive health counseling</strong> – Females of reproductive age should be screened for pregnancy before starting a JAK inhibitor and counseled appropriately with respect to reproductive risk. (See <a class="local">'Restrictions'</a> below and <a class="local">'Reproductive health concerns'</a> below and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tofacitinib'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Limited information'</a>.)</p><p></p><p class="headingAnchor" id="H1361551265"><span class="h2">Restrictions</span><span class="headingEndMark"> — </span>Restrictions to consider when initiating a JAK inhibitors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent treatment with other DMARDs</strong> – JAK inhibitors should not be given in combination with biologic disease-modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants such as <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. Clinical trials testing <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> in transplant patients in combination with <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>/cyclosporine demonstrated increased adverse events, including post-transplant lymphoproliferative disease [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Requirement for prior use of alternative therapies in selected patients</strong> – Several government agencies have recommended avoiding the use of JAK inhibitors in patients with certain risk factors when alternative therapies are available. This is based on data showing higher rates of malignancy and major adverse cardiovascular events (MACE) with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> compared with <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>/<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> in a population of patients with rheumatoid arthritis (RA) who were over 50 years of age and enriched for cardiovascular risk factors. (See <a class="local">'Overview of adverse effects'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The FDA has advised limiting use of the JAK inhibitors <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> to patients with immune-mediated inflammatory diseases, including RA, who have not adequately responded to or who are intolerant of first-line biologic therapy, typically a TNF inhibitor [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended that JAK inhibitors should not be used in the following patients unless no suitable treatment alternatives are available: those aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past, and those at increased risk of cancer [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients ≥65 years (European recommendations)</strong> – The EMA has recommended only using JAK inhibitors in patients over 65 years of age if no suitable treatment alternatives are available [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk factors</strong> – Given the potential increased risk of serious cardiac events (eg, myocardial infarction, stroke, venous thromboembolus, pulmonary embolus), the FDA has advised assessing whether the benefits outweigh the risks for the individual patient prior to initiating or continuing therapy with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> for arthritis and other inflammatory conditions, particularly in patients who are current or past smokers and those with other cardiovascular risk factors [<a href="#rid26">26</a>]. The EMA recommends against using JAK inhibitors for patients with increased risk of major cardiovascular problems and/or current or prior significant tobacco use, as long as there are suitable alternative therapies. [<a href="#rid27">27</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy – </strong>Given the potential increased risk of malignancy (eg, lymphoma, lung cancer), the FDA and EMA have advised assessing whether the benefits outweigh the risks for the individual patient prior to initiating or continuing therapy with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, and filgotinib for arthritis and other inflammatory conditions, particularly in patients who develop a malignancy or who have a known malignancy other than a successfully treated nonmelanoma skin cancer [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboembolic disease</strong> – JAK inhibitors should be used with caution in patients with increased risk for or personal history of thrombosis. Alternative agents should be selected if available. If no alternative agents are available, patients should be educated regarding signs and symptoms of thrombosis and counseled to seek care immediately if these develop. (See <a class="local">'Cardiovascular'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal disease</strong> – JAK inhibitors should be used with caution in patients at increased risk of gastrointestinal perforation, particularly patients with a history of diverticulitis. Alternative agents should be selected if available. If no alternative agents are available, patients should be educated regarding signs and symptoms of gastrointestinal perforation and counseled to seek care immediately if these develop. (See <a class="local">'Gastrointestinal'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphopenia, neutropenia, and anemia</strong> – Initiation of JAK inhibitors should be avoided in patients with baseline absolute lymphocyte count (ALC) &lt;500 cells/mm<sup>3</sup> or absolute neutrophil count (ANC) &lt;1000 cells/mm<sup>3</sup> and in patients with baseline hemoglobin &lt;8 g/dL (<a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>) or 9 g/dL (<a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Active infection should be excluded prior to initiation of JAK inhibitors. For patients with clinically important active bacterial or viral infections, we withhold JAK inhibitors until the course of antibiotic or antiviral agent is complete and until patients appear to have clinical resolution of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative considerations</strong> – JAK inhibitor therapy may increase the risk of perioperative infection. The approach to perioperative medication management for patients using JAK inhibitors with rheumatic disease is described separately, and a similar approach is used for other conditions. (See  <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">"Preoperative evaluation and perioperative management of patients with rheumatic diseases", section on 'Medication management'</a> and  <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">"Preoperative evaluation and perioperative management of patients with rheumatic diseases", section on 'Janus kinase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – Use should be avoided in pregnancy. Additional information regarding safety during pregnancy and breastfeeding is provided separately, including in the respective drug information topics for each agent. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tofacitinib'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Limited information'</a>.)</p><p></p><p class="headingAnchor" id="H2986501066"><span class="h2">Vaccination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment vaccination</strong> – Patients preferably should be immunized appropriately prior to starting JAK inhibitor therapy because these agents increase the risk of certain infections, including herpes zoster [<a href="#rid28">28</a>] and streptococcal pneumonia [<a href="#rid29">29</a>]. Live and attenuated viral vaccines are avoided in patients under treatment with JAK inhibitors. The approach to immunization of patients with autoimmune and inflammatory rheumatic disease is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination during treatment</strong> – Live or live-attenuated vaccines should generally not be administered during treatment. (See  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults", section on 'Timing of vaccination'</a> and  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults", section on 'Live vaccines'</a>.)</p><p></p><p class="bulletIndent1">Recommendations regarding use of vaccines for COVID-19 infection are described separately. (See  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 vaccination while on immunosuppressive therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2604985086"><span class="h1">DOSING AND DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Each of the Janus kinase (JAK) inhibitors is metabolized and transported in a unique fashion, and for each agent dosing may differ between different disorders and may be affected by renal and hepatic status and concomitant use of other medications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The dosing for each agent is described in the topic reviews where the use of the medication for a given condition is discussed (see appropriate topic reviews). Dosing and adjustments for renal and hepatic dysfunction for these agents are described elsewhere. (See <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> drug information; see <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> drug information; see <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> drug information; see <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a> drug information.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – The range of potential drug interactions differs between the individual agents, but some require dose modification or avoidance of particular drug combinations. Thus, patients receiving JAK inhibitors should have their medication regimen analyzed for drug interactions, particularly when initiating and adjusting therapy; this may be done by use of the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1">As examples, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> metabolism is increased by rifampicin, a strong CYP3A4 inducer, whereas tofacitinib metabolism may be decreased by strong CYP3A4 inhibitors, such as <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, increasing levels of tofacitinib. <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">Baricitinib</a> may interact with organic anion transporter 3 inhibitors, such as <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>, resulting in increased serum drug levels. Filgotinib is primarily metabolized by carboxylesterase 2, which is inhibited in vitro by drugs such as <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">fenofibrate</a>, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, and <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, although the clinical relevance of this interaction is unknown [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H3381652281"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2194715308"><span class="h2">Overview of adverse effects</span><span class="headingEndMark"> — </span>The most commonly reported adverse events associated with Janus kinase (JAK) inhibitors are generally not serious and have included upper respiratory infections, urinary tract infections, and nasopharyngitis, as well as nausea, headache, and occasional diarrhea. (See <a class="local">'Infection'</a> below and <a class="local">'Gastrointestinal'</a> below.)</p><p>An increased risk of gastrointestinal perforations and serious infections including herpes zoster, tuberculosis, and opportunistic infections has been described. However, these and other major risks are generally similar (except for a greater risk of herpes zoster) to those for the biologic disease-modifying antirheumatic drugs (bDMARDs), such as interleukin (IL) 6 inhibitors and tumor necrosis factor (TNF) inhibitors, which are used in similar populations of patients with immune-mediated inflammatory diseases. (See <a class="local">'Infection'</a> below and <a class="local">'Gastrointestinal'</a> below and  <a class="medical medical_review" href="/z/d/html/129345.html" rel="external">"Interleukin 6 inhibitors: Biology, principles of use, and adverse effects", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p>There has also been concern for a small increase in absolute risk of all-cause mortality, cardiovascular events, stroke, and malignancy with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> compared with TNF inhibitors in older patients with rheumatoid arthritis (RA) [<a href="#rid31">31</a>]. In a phase 3B/4 US Food and Drug Administration (FDA)-mandated clinical trial (ORAL Surveillance) post tofacitinib approval, an imbalance with tofacitinib compared with <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>/<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> was reported for the rate of malignancy and major adverse cardiovascular events (MACE) in a population of patients with RA who were over 50 years of age and enriched for cardiovascular risk factors. Additionally, an increased risk of venous thromboembolism in a dose-dependent fashion was reported [<a href="#rid31">31</a>]. A post hoc analysis of the data reported greatest risk in patients with RA who were over age 65 and were previous or current smokers [<a href="#rid32">32,33</a>]. A possible increased risk of venous thromboembolism has also been observed with both <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> and tofacitinib. (See <a class="local">'Cardiovascular'</a> below and <a class="local">'Malignancy'</a> below.)</p><p>The underlying mechanism of the increased risk for venous thromboembolism, malignancy, or MACE is unknown. Prospective studies evaluating possible biomarkers associated with thrombosis are ongoing in patients treated with JAK inhibitors, as well as a large clinical trial with similar design to ORAL Surveillance evaluating <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid34">34</a>].</p><p>Most patients do not require any adjustment to therapy based on laboratory findings. Laboratory abnormalities include lymphopenia, neutropenia, anemia, dyslipidemia, and elevated liver enzymes; nonsignificant elevations of creatine phosphokinase and serum creatinine have also been noted [<a href="#rid15">15,35-48</a>]. (See <a class="local">'Hematologic'</a> below and <a class="local">'Gastrointestinal'</a> below.)</p><p class="headingAnchor" id="H3520804641"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Overall, the risk of infection in patients treated with JAK inhibitors appears to be in line with what is seen for patients treated with bDMARDs, including TNF inhibitors, with the exception of the incidence of herpes zoster, which is increased with all the JAK inhibitors but not with the bDMARDs [<a href="#rid49">49</a>]. JAK inhibitors should not be given in combination with other biologic agents. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes zoster</strong> – With <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, herpes zoster infections were reported at a rate of 3.4 per 100 patient-years, which is higher than what is seen with conventional synthetic DMARDs (csDMARDs) or bDMARDs [<a href="#rid36">36,49,50</a>]. Among patients with herpes zoster, 90.2 percent had herpes zoster in a single dermatome and 7.3 percent were considered to have serious herpes zoster infections. Use of glucocorticoids in conjunction with JAK inhibitors appears to further increase the incidence of herpes zoster.</p><p></p><p class="bulletIndent1">Whenever possible, patients should be vaccinated for herpes zoster prior to initiation of a JAK inhibitor (see <a class="local">'Vaccination'</a> above). For patients who develop herpes zoster while receiving a JAK inhibitor, it is the authors' practice to temporarily withhold the JAK inhibitor until the patient has shown clinical improvement and has completed a course of antiviral therapy. Patients with complicated herpes zoster or recurrent herpes zoster may be switched to an alternative therapy with a different mechanism of action or the patient may be treated with daily suppressive antiviral therapy indefinitely if the JAK inhibitor needs to be resumed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – Tuberculosis has been reported in clinical trials of all of the JAK inhibitors. Incidence rates are similar to those seen with bDMARDs, 0.1 to 0.22 per 100 patient-years, and are primarily seen with their use in geographic areas endemic for tuberculosis [<a href="#rid36">36,51</a>]. Most cases of tuberculosis in clinical trials were primary infection, although there were cases of reactivation of latent tuberculosis [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Screening for latent tuberculosis should be performed prior to initiating JAK inhibitors (see <a class="local">'Clinical and laboratory screening and evaluation'</a> above). There are currently no established guidelines for duration of treatment of latent tuberculosis prior to initiation of JAK inhibitors. It is the author's practice to treat patients diagnosed with latent tuberculosis with antimicrobials as per World Health Organization (WHO) guidelines for at least two to four weeks prior to initiating JAK inhibitors. For patients with active tuberculosis, the JAK inhibitor should be held while treatment is initiated and until there is clear clinical improvement [<a href="#rid36">36,49</a>]. The decision of whether or when to resume JAK inhibitor therapy should be made on an individual basis, typically in consultation with an infectious disease specialist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opportunistic infections</strong> – Opportunistic infections have been reported in patients treated with JAK inhibitors at rates of 0.1 to 0.3 per 100 patient-years, with rates similar to those seen in trials of bDMARDs. Opportunistic infections include multidermatomal herpes zoster, esophageal candidiasis, pneumocystis, cytomegalovirus (CMV), and cryptococcal infections [<a href="#rid36">36,51,52</a>]. JAK inhibitors should be held upon diagnosis of opportunistic infections, while treatment of the infection is initiated. Decisions regarding whether or when to resume JAK inhibitor therapy should be made on an individual basis in consultation with an infectious disease specialist, based upon the severity of infection, risk of morbidity and mortality due to infection, and risk of morbidity and mortality related to progression of the patient's underlying condition for which the JAK inhibitor was initiated.</p><p></p><p class="headingAnchor" id="H3312965522"><span class="h2">Cardiovascular</span><span class="headingEndMark"> — </span>Patients are at increased risk for dyslipidemia and may be at risk for thrombotic and other cardiovascular events.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyslipidemia</strong> – Elevations in total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) have been reported, typically in the range of 10 to 20 percent of patients [<a href="#rid53">53,54</a>]. The HDL/LDL ratio is generally unchanged. Elevations are usually noted within 12 weeks of starting treatment and are usually stable thereafter. Dyslipidemia should be managed according to available guidelines, using the same approaches as in patients not being treated with these agents. Studies have suggested this increase in cholesterol is associated with improvement in inflammation [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular and cerebrovascular</strong> – There is concern that JAK inhibitors may be associated with an increased risk of cardiovascular events, particularly among patients who already have risk factors. However, this has not been demonstrated consistently across studies.</p><p></p><p class="bulletIndent1">A nationwide registry representing the population of France demonstrated an increased incidence of MACE (defined as cardiovascular death, myocardial infarction, stroke, and all-cause mortality), but the difference was not statistically significant (4.3 versus 3.6 per 1000 person-years, weighted hazard ratio [HR] 1.0, 95% CI 0.7-1.5) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Similarly, the FDA reported an increase in nonfatal myocardial infarction (0.35 versus 0.16 events per 100 person-years, HR 2.20, 95% CI 1.02-4.75) and a trend towards an increase in MACE that did not reach statistical significance (0.98 versus 0.73 events per 100 person-years, HR 1.33, 95% CI 0.91-1.94) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> may be associated with an increased risk of cardiovascular events primarily among patients with a prior history of atherosclerotic disease. ORAL Surveillance was a large postmarketing open-label randomized trial with a median follow-up of four years. The study enrolled 4362 patients who were taking <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, were at least 50 years old, and had at least one risk factor for heart disease [<a href="#rid31">31</a>]. A post-hoc analysis demonstrated an increased risk of MACE primarily among patients with a history of atherosclerotic disease. In patients without atherosclerotic disease, tofacitinib 5 mg twice daily was not associated with an increased risk of MACE when compared with TNF inhibitors [<a href="#rid32">32</a>].</p><p></p><p>The FDA and European Medicines Agency (EMA) have each issued guidance for use of these agents based upon the available data. (See <a class="local">'Clinical and laboratory screening and evaluation'</a> above and <a class="local">'Restrictions'</a> above.)</p><p class="headingAnchor" id="H3996895318"><span class="h2">Venous thromboembolic events</span><span class="headingEndMark"> — </span>JAK inhibitors may be associated with an increased risk of venous thrombotic events, especially pulmonary embolism. This risk may be highest for patients taking either <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> or <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>.</p><p>A nationwide registry representing the population of Sweden observed an increased number of venous thrombolic events in patients treated with JAK inhibitors versus TNF inhibitors (11.3 versus 5.2 events per 1000 person-years) [<a href="#rid56">56</a>]. This increase was attributed to an increased risk of pulmonary embolism (adjusted HR 3.21, 95% CI 2.11-4.88). A nationwide registry representing the population of France also observed a higher number of venous thromboembolic events in patients treated with JAK inhibitors versus TNF inhibitors (6.0 versus 3.3 events per 1000 person-years), but the difference was not statistically significant (weighted HR 1.1, 95% CI 0.7-1.6) [<a href="#rid55">55</a>].</p><p>The risk of venous thrombolic events may be higher with specific JAK inhibitors. An increased risk of thrombosis was previously reported in the placebo-controlled trials of <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid57">57</a>]. The FDA reported a dose-dependent increased risk associated with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> compared with TNF inhibitors of venous thromboembolic events, including pulmonary embolism [<a href="#rid31">31</a>]. However, an increased risk has not been reported for <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> or filgotinib [<a href="#rid58">58-60</a>].</p><p class="headingAnchor" id="H347909352"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>JAK inhibitors may be associated with an increased risk of certain types of cancer. The FDA and EMA have each issued guidance for use of these agents based upon the available data. (See <a class="local">'Clinical and laboratory screening and evaluation'</a> above and <a class="local">'Restrictions'</a> above.)</p><p>Data to support the relationship between JAK inhibitors and malignancy risk are mixed. In the clinical trial program for several approved JAK inhibitors (<a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>), no increase in malignancies was reported compared with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid36">36,60,61</a>]. However, in the ORAL Surveillance study of patients 50 years and older with elevated cardiovascular risk, the results suggested an increased risk of malignancy, particularly lung cancer and lymphoma, in patients on tofacitinib compared with the patients treated with a TNF inhibitor (1.13 versus 0.77 events per 100 person-years, HR 1.48, 95% CI 1.04-2.09) [<a href="#rid31">31</a>]. Lung cancer was seen particularly in current or past smokers. In a post hoc analysis, patients receiving tofacitinib had higher incidence rates of malignancy including non-melanoma skin cancer compared with patients receiving TNF inhibitors; incidence rates were highest for patients with a history or higher risk of atherosclerotic cardiovascular disease [<a href="#rid62">62</a>].</p><p>Multiple observational studies of patients with RA published after the ORAL Surveillance study have not found significantly higher rates of malignancy in those taking JAK inhibitors [<a href="#rid63">63-65</a>]. As an example, in a large observational cohort study of over 5000 adults with RA in the Danish nationwide registry, the risk of first primary cancer was not significantly higher in patients taking JAK inhibitors (<a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> or <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>) compared with those taking other bDMARDs [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3417420027"><span class="h2">Hematologic</span><span class="headingEndMark"> — </span>The hematologic adverse events seen with JAK inhibitors are probably due in large part to inhibition of JAK1 and the resultant suppression of IL-6 signaling through its receptor [<a href="#rid15">15,36-44,46,47,61</a>]. Treatment should be temporarily interrupted in patients with an absolute neutrophil count (ANC) &lt;1000 cells/mm<sup>3</sup>, absolute lymphocyte count (ALC) &lt;500 cells/mm<sup>3</sup>, or hemoglobin &lt;8 to 9 g/dL observed during routine patient monitoring, with subsequent dose reduction to maintain adequate levels if treatment is continued [<a href="#rid30">30</a>]. (See <a class="local">'Infection'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – Modest neutropenia that is not clinically significant is seen with use of all JAK inhibitors, with rare grade 3/4 neutropenia (ANC &lt;1000/ cells/mm<sup>3</sup>) and no association with increased infection risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphopenia</strong> – JAK3 inhibition is most likely responsible for lymphopenia, although this has been reported with all the JAK inhibitors. Grade 4 lymphopenia (ALC &lt;500 cells/mm<sup>3</sup>) was rarely seen in the clinical trials of <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> and was not associated with increased serious infectious risk. All the approved JAK inhibitors have warnings to not initiate treatment or discontinue treatment in patients with ALC &lt;500 cells/mm3.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – Significant anemia is unusual with JAK inhibitors.</p><p></p><p class="headingAnchor" id="H460083855"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Patients treated with JAK inhibitors are at increased risk for abnormalities in liver function and gastrointestinal perforation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated liver enzymes</strong> – Transaminase elevation has been observed with all JAK inhibitors, particularly when used in combination with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, with rates similar to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> and methotrexate in clinical trials. Liver chemistry abnormalities typically resolve with dose reduction or discontinuation [<a href="#rid15">15,36-44,46,47,61</a>].</p><p></p><p class="bulletIndent1">If transaminase elevations occur in patients who are also on <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, it is the authors' practice to reduce or discontinue the methotrexate. Rarely it also may be necessary to reduce the dose of the JAK inhibitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms and gastrointestinal tract perforation</strong> – In clinical trials, nausea has been reported with all the JAK inhibitors, and diarrhea has been noted with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> in a small percentage of patients. Gastrointestinal perforations were described in a small number of patients in clinical trials of the JAK inhibitors. They were rare, occurring with an incidence rate of approximately 0.1 per 100 patient-years, which is similar to the frequency reported with IL-6 inhibitors [<a href="#rid36">36</a>]. Perforation events were primarily seen in patients concurrently treated with nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids.</p><p></p><p class="bulletIndent1">JAK inhibitors should be avoided, if possible, in patients with a history of diverticulitis, given the increased risk of colon perforation in patients with diverticulitis [<a href="#rid66">66</a>]. In patients who develop perforation while on a JAK inhibitor, the authors avoid further use of JAK inhibitors.</p><p></p><p class="headingAnchor" id="H4006145548"><span class="h2">Reproductive health concerns</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and lactation</strong> – The JAK inhibitors are teratogens in animal models; studies in humans are lacking. Additional information regarding safety during pregnancy and breastfeeding is provided separately, including in the respective drug information topics for each agent. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tofacitinib'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Limited information'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Male fertility</strong> – Preclinical studies suggested that filgotinib may impair male fertility; this appears to be an issue unique to filgotinib, and the mechanism remains unknown. In animal studies of filgotinib, adverse effects on male reproductive organs were observed, including impaired spermatogenesis and decreased fertility [<a href="#rid67">67</a>]. The potential effect of filgotinib on sperm production and male fertility in humans is unknown, as is the reversibility of these potential effects.</p><p></p><p class="bulletIndent1">FDA concerns regarding male fertility, particularly with the 200 mg dose of filgotinib, influenced the FDA's decision not to approve filgotinib without additional studies. Initially, EMA package labeling for filgotinib includes a special warning regarding male fertility [<a href="#rid30">30</a>]. Studies on the impact of filgotinib on male spermatogenesis were conducted in patients with inflammatory bowel disease and RA. A press release of the data noted that there was no difference from placebo in spermatogenesis at 13 weeks treatment. Based upon further data review by the EMA, the warning of impact on male spermatogenesis has been removed from the package insert [<a href="#rid68">68,69</a>].</p><p></p><p class="headingAnchor" id="H2495759919"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>The approach to monitoring for drug toxicities is similar for all of the agents, although disease-specific concerns should also be considered. Janus kinase (JAK) inhibitors may have a disproportionate effect upon measures of inflammation and disease activity (eg, in rheumatoid arthritis [RA]) because of their suppressive effect on acute phase reactants, particularly on levels of C-reactive protein, that are independent of their clinical impact on arthritis disease activity (as measured by composite instruments that do not use acute phase measurements). This biologic effect is similar to the that of interleukin (IL) 6/IL-6R pathway inhibitors. (See  <a class="medical medical_review" href="/z/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Disease Activity Score using 28 joints (DAS28)'</a>.)</p><p>We generally perform the following monitoring for drug-related effects, similar to the approach in RA:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical monitoring</strong> – Patients should be monitored for the following [<a href="#rid38">38</a>] (see <a class="local">'Adverse effects'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of infection, including viral infections, such as herpes zoster, and tuberculosis</p><p class="bulletIndent2"><span class="glyph">•</span>New onset of gastrointestinal symptoms that may suggest diverticulitis or gastrointestinal perforation</p><p class="bulletIndent2"><span class="glyph">•</span>Signs and symptoms of thrombosis or cardiovascular disease in patients at higher risk for these events</p><p class="bulletIndent2"><span class="glyph">•</span>Other adverse effects</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – The approach to laboratory monitoring in patients being treated with a JAK inhibitor for a systemic inflammatory or rheumatologic disorder (eg, RA or psoriatic arthritis) is similar irrespective of the specific JAK inhibitor prescribed for these indications. Monitoring for patients with other conditions in which JAK inhibitors may also be used, such as hematologic disorders, may differ.</p><p></p><p class="bulletIndent1">Laboratory monitoring in patients with a systemic inflammatory or rheumatologic disorder should include the following after baseline studies (see <a class="local">'Clinical and laboratory screening and evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete blood count with differential</strong> – Following baseline studies, a complete blood count and differential white blood cell count should be obtained after four to eight weeks of therapy, then every three months. Treatment should be temporarily interrupted in patients with an absolute neutrophil count (ANC) &lt;1000 cells/mm<sup>3</sup>, absolute lymphocyte count (ALC) &lt;500 cells/mm<sup>3</sup>, or hemoglobin &lt;8 to 9 g/dL observed during routine patient monitoring, with dose reduction to maintain adequate levels if treatment is to be continued [<a href="#rid30">30</a>]. (See <a class="local">'Infection'</a> above and <a class="local">'Hematologic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver function tests</strong> – Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and bilirubin) are performed periodically following baseline studies. The authors typically obtain liver function tests after four to eight weeks of therapy, and then every three months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lipids</strong> – A lipid panel including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, should be obtained 8 to 12 weeks after starting therapy and periodically thereafter, based upon usual guidance for screening and follow-up in patients not receiving JAK inhibitors. (See <a class="local">'Gastrointestinal'</a> above.)</p><p></p><p class="headingAnchor" id="H2646993274"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112604.html" rel="external">"Society guideline links: Juvenile idiopathic arthritis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H2599056974"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Janus kinase biology and function</strong> – Janus kinases (JAKs) are protein tyrosine kinases (TYKs) that bind to the intracellular domains of transmembrane cytokine receptors of several different cytokines and growth factors  (<a class="graphic graphic_figure graphicRef132371" href="/z/d/graphic/132371.html" rel="external">figure 1</a>). When the receptors are bound by their respective extracellular ligands, the JAKs become activated and phosphorylate both the receptor and the cognate signal transducer and activator of transcription (STAT) proteins. The STAT proteins then dimerize and enter the nucleus where they bind to transcriptional regulatory sites and mediate cellular responses important in immune defense, as well as immune-mediated disease. (See <a class="local">'Janus kinase biology and function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action of Janus kinase inhibitors</strong> – JAK inhibitors (JAKi or Jakinibs) are small, orally active drugs that are categorized as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and have generally similar risks as the biologic DMARDs (bDMARDs) in treating immune-mediated inflammatory disease. Several agents are available for pharmacologic JAK inhibition. JAK inhibitors available for clinical use differ in their selectivity for specific JAK isoforms. However, it is not clear how this apparent JAK selectivity in the laboratory and in experimental animal models extrapolates to meaningful differences among these agents in their clinical efficacy across the spectrum of chronic inflammatory diseases. (See <a class="local">'Mechanism of action of Janus kinase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment screening and precautions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pretreatment screening</strong> – Baseline laboratory studies should include a complete blood count, differential, and platelet count; liver function tests; and a lipid panel. Patients should also be screened for latent tuberculosis and hepatitis B and C and cardiovascular and malignancy risk factors. Females of reproductive age should be screened for pregnancy. (See <a class="local">'Pretreatment screening and precautions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Restrictions</strong> – JAK inhibitors should not be given in combination with other biologic agents and should be held in the presence of active infection and/or surgery. JAK inhibitors should be avoided in people who are pregnant or considering pregnancy.</p><p></p><p class="bulletIndent2">A reported numeric increase in venous thromboembolisms, malignancy, and major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> compared with tumor necrosis factor (TNF) inhibitors has resulted in a boxed warning limiting use to patients with immune-mediated inflammatory diseases who have failed first-line biologic therapies. Risks and benefits of JAK inhibitor use should be carefully weighed for patients who are over age 65 years of age and/or who have a history of or risk factors for malignancy, cardiovascular disease, thromboembolic disease, and/or gastrointestinal perforation. (See <a class="local">'Restrictions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccination</strong> – Patients should preferably be immunized with appropriate vaccines prior to therapy; live or live-attenuated vaccines are not recommended during treatment. (See <a class="local">'Vaccination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most commonly reported adverse events associated with JAK inhibitors are upper respiratory infections, nausea, headache, nasopharyngitis, and diarrhea. Infections, particularly herpes zoster, are the most frequent serious adverse events reported. Venous thrombosis, thromboembolism, nonfatal myocardial infarction, lung cancer, and lymphoma may occur at an increased rate. Gastrointestinal perforation can rarely occur in adults. Laboratory abnormalities include neutropenia, thrombocytopenia, dyslipidemia, and elevated liver enzymes. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients should be monitored for signs or symptoms of infectious, gastrointestinal, or thrombotic complications. Laboratory monitoring includes blood counts, liver function tests, and lipid levels. (See <a class="local">'Adverse effects'</a> above and <a class="local">'Monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273.</a></li><li><a class="nounderline abstract_t">Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415.</a></li><li><a class="nounderline abstract_t">O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66:311.</a></li><li><a class="nounderline abstract_t">Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 2017; 18:374.</a></li><li><a class="nounderline abstract_t">Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect 2019; 7:e00537.</a></li><li><a class="nounderline abstract_t">McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 2019; 21:183.</a></li><li><a class="nounderline abstract_t">Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191:3568.</a></li><li><a class="nounderline abstract_t">Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127.</a></li><li><a class="nounderline abstract_t">Tanaka Y, Sugiyama N, Toyoizumi S, et al. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Rheumatology (Oxford) 2019; 58:70.</a></li><li><a class="nounderline abstract_t">Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184:5298.</a></li><li><a class="nounderline abstract_t">Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018; 2:23.</a></li><li class="breakAll">European Medicines Agency: Jyseleca (filgotinib). https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca (Accessed on November 20, 2022).</li><li><a class="nounderline abstract_t">Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet 2022; 61:819.</a></li><li><a class="nounderline abstract_t">Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 2021; 80:865.</a></li><li><a class="nounderline abstract_t">Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 2019; 78:1305.</a></li><li><a class="nounderline abstract_t">Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs 2016; 30:407.</a></li><li><a class="nounderline abstract_t">Papp K, Gordon K, Thaçi D, et al. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med 2018; 379:1313.</a></li><li><a class="nounderline abstract_t">Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. J Invest Dermatol 2020; 140:2359.</a></li><li><a class="nounderline abstract_t">Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 2022; 81:815.</a></li><li class="breakAll">A study to investigate the efficacy and safety of brepocitinib in adults with dermatomyositis (VALOR). Available at: https://clinicaltrials.gov/ct2/show/NCT05437263 (Accessed on October 07, 2022).</li><li><a class="nounderline abstract_t">Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75:1133.</a></li><li><a class="nounderline abstract_t">Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 2018; 77:780.</a></li><li><a class="nounderline abstract_t">Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open 2020; 6.</a></li><li><a class="nounderline abstract_t">Chen YM, Huang WN, Liao TL, et al. Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. Ann Rheum Dis 2019; 78:849.</a></li><li><a class="nounderline abstract_t">Zand MS. Tofacitinab in renal transplantation. Transplant Rev (Orlando) 2013; 27:85.</a></li><li class="breakAll">FDA Drug Safety Communication. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (Accessed on September 06, 2021).</li><li class="breakAll">EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic (Accessed on November 26, 2022).</li><li><a class="nounderline abstract_t">Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis 2020; 12:1759720X20936059.</a></li><li><a class="nounderline abstract_t">Khoo JK, Barnes H, Key S, et al. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford) 2020; 59:2217.</a></li><li class="breakAll">Jyseleca: Product information. Available at: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf (Accessed on January 24, 2021).</li><li><a class="nounderline abstract_t">Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386:316.</a></li><li><a class="nounderline abstract_t">Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis 2023; 82:119.</a></li><li><a class="nounderline abstract_t">Curtis JR, Yamaoka K, Chen Y, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 2022.</a></li><li class="breakAll">A Study of baricitinib in participants with rheumatoid arthritis (RA-BRANCH). Available at: https://clinicaltrials.gov/ct2/show/NCT04086745 (Accessed on October 07, 2022).</li><li><a class="nounderline abstract_t">Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021; 80:71.</a></li><li><a class="nounderline abstract_t">Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019; 21:89.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Takeuchi T, Schiff M, et al. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care Res (Hoboken) 2020; 72:1112.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017; 390:457.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol 2019; 71:1788.</a></li><li><a class="nounderline abstract_t">Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 2019; 78:1454.</a></li><li><a class="nounderline abstract_t">Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA 2019; 322:315.</a></li><li><a class="nounderline abstract_t">Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol 2020; 79:785.</a></li><li><a class="nounderline abstract_t">Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol 2017; 69:932.</a></li><li><a class="nounderline abstract_t">Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis 2019; 78:1320.</a></li><li><a class="nounderline abstract_t">Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther 2014; 16:R158.</a></li><li><a class="nounderline abstract_t">Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 2021; 80:848.</a></li><li><a class="nounderline abstract_t">Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 2021; 80:727.</a></li><li><a class="nounderline abstract_t">Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 2022; 81:335.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Citera G, Gold D, et al. Age-based (&lt;65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis 2021; 80:134.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol 2017; 69:1960.</a></li><li><a class="nounderline abstract_t">Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66:2924.</a></li><li><a class="nounderline abstract_t">Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019; 58:1755.</a></li><li><a class="nounderline abstract_t">Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum 2016; 46:71.</a></li><li><a class="nounderline abstract_t">McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014; 73:124.</a></li><li><a class="nounderline abstract_t">Hoisnard L, Pina Vegas L, Dray-Spira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 2023; 82:182.</a></li><li><a class="nounderline abstract_t">Molander V, Bower H, Frisell T, et al. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis 2023; 82:189.</a></li><li><a class="nounderline abstract_t">Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol 2019; 46:7.</a></li><li><a class="nounderline abstract_t">Yates M, Mootoo A, Adas M, et al. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol 2021; 73:779.</a></li><li><a class="nounderline abstract_t">Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis 2020; 79:1400.</a></li><li><a class="nounderline abstract_t">Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2021; 80:304.</a></li><li><a class="nounderline abstract_t">Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol 2020; 2:e347.</a></li><li><a class="nounderline abstract_t">Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 2023; 82:331.</a></li><li><a class="nounderline abstract_t">Westermann R, Cordtz RL, Duch K, et al. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford) 2024; 63:93.</a></li><li><a class="nounderline abstract_t">Kremer JM, Bingham CO 3rd, Cappelli LC, et al. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatol 2021; 3:173.</a></li><li><a class="nounderline abstract_t">Khosrow-Khavar F, Desai RJ, Lee H, et al. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol 2022; 74:1648.</a></li><li><a class="nounderline abstract_t">Xie F, Yun H, Bernatsky S, Curtis JR. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis Rheumatol 2016; 68:2612.</a></li><li class="breakAll">https://www.ema.europa.eu/en/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf (Accessed on January 24, 2021).</li><li class="breakAll">Galapagos reports primary endpoint for the ongoing filgotinib manta and MANTA-RAy safety studies. https://www.globenewswire.com/news-release/2021/03/04/2186756/0/en/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-THE-ONGOING-FILGOTINIB-MANTA-AND-MANTA-RAy-SAFETY-STUDIES.html (Accessed on November 26, 2022).</li><li class="breakAll">Galapagos receives positive CHMP opinion for Jyseleca® European label
update based on testicular function safety data from MANTA/RAy
studies. https://ml-eu.globenewswire.com/Resource/Download/153098fa-8d43-4c31-9844-682b0708c457 (Accessed on November 26, 2022).</li></ol></div><div id="topicVersionRevision">Topic 130611 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19290934" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Janus kinases in immune cell signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8197455" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25587654" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The JAK-STAT pathway: impact on human disease and therapeutic intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323260" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanisms and consequences of Jak-STAT signaling in the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31832202" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375130" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24006460" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18183025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A quantitative analysis of kinase inhibitor selectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137547" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363976" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30886973" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30886973" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35637376" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Filgotinib: A Clinical Pharmacology Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33741556" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350269" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27577235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30205746" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32311398" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35241426" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35241426" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318385" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28663308" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32098857" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606739" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849222" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tofacitinab in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849222" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tofacitinab in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849222" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tofacitinab in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32655703" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : JAK inhibitors and infections risk: focus on herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32406509" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32406509" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081280" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36137735" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33158881" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953540" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31233281" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28629665" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31287230" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31362993" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334793" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32055928" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118538" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350270" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063045" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33504485" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33452004" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34706874" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046447" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Age-based (&lt;65 vs≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845604" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047021" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982883" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27079757" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23482473" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198438" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36150749" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30219772" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33174384" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759265" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33115760" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38273598" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600185" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37052534" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570260" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643956" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27213279" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
